Loading...
•
Dec 31, 2025
Kymera Therapeutics Q4 2025 Earnings Report
Kymera Therapeutics reported increased operating expenses and a wider net loss for the fourth quarter of 2025 while maintaining a strong cash position.
Key Takeaways
For Q4 2025, Kymera reported collaboration revenue of 2871000 and a net loss of 86981000, driven by higher research and development expenses of 83831000, while ending the year with 1619434000 in cash, cash equivalents and marketable securities.
Collaboration revenue was 2871000 in Q4 2025, down from the prior year period.
Research and development expenses increased to 83831000 in Q4 2025.
Net loss widened to 86981000 for the quarter.
Cash, cash equivalents and marketable securities totaled 1619434000 as of December 31, 2025.
Forward Guidance
Kymera expects its cash balance of 1619434000 as of December 31, 2025 to provide runway into 2029 beyond multiple clinical inflection points.
Positive Outlook
- Cash runway expected into 2029.
- KT-621 Phase 2b trials in atopic dermatitis and asthma ongoing.
- KT-579 Phase 1 healthy volunteer trial initiated.
- Completed 602000000 underwritten equity offering with approximately 692000000 in gross proceeds.
- Fast Track designation granted to KT-621 for moderate to severe atopic dermatitis.
Challenges Ahead
- Net loss increased year-over-year in Q4 2025.
- Research and development expenses rose compared to prior year.
- General and administrative expenses increased year-over-year.
- Operating loss widened compared to Q4 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...